Literature DB >> 17694388

Evaluation of serotonin, noradrenaline and dopamine reuptake inhibitors on light-induced phase advances in hamster circadian activity rhythms.

Robert L Gannon1, Mark J Millan.   

Abstract

RATIONALE: Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for the treatment of anxiodepressive states that are often associated with perturbed circadian rhythms including, in certain patients, phase advances. Surprisingly, the influence of SSRIs upon circadian activity rhythms has been little studied in experimental models.
OBJECTIVES: Accordingly, this study examined the ability of SSRIs to modulate the phase-setting properties of light on circadian activity rhythms in hamsters. Their actions were compared to those of the mixed serotonin/noradrenaline reuptake inhibitor (SNRI), venlafaxine, the selective noradrenaline reuptake inhibitor, reboxetine, and the dopamine reuptake inhibitor, bupropion.
MATERIALS AND METHODS: Wheel-running activity rhythms were recorded in male Syrian hamsters. Drugs were administered systemically before a light stimulus that was used to advance the timing of the hamster running rhythms.
RESULTS: Four chemically diverse SSRIs, citalopram (1-10 mg/kg, intraperitoneally), fluvoxamine (1-10), paroxetine (1-10), and fluoxetine (10 and 20), all robustly and significantly inhibited the ability of light to phase advance hamster circadian wheel-running activity rhythms. Their actions were mimicked by venlafaxine (1-10) that likewise elicited a marked reduction in phase advances. Conversely, reboxetine (1-20) and bupropion (1-20) did not exert significant effects.
CONCLUSIONS: These data suggest that suppression of serotonin (but not noradrenaline or dopamine) reuptake by SSRIs and SNRIs modifies circadian locomotor activity rhythms in hamsters. Further, they support the notion that an inhibitory influence upon the early-morning light-induced advance in circadian activity contributes to the therapeutic effects of serotonin uptake inhibitors in certain depressed patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17694388     DOI: 10.1007/s00213-007-0903-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  72 in total

1.  Anatomical and functional characterisation of a dopaminergic system in the suprachiasmatic nucleus of the neonatal Siberian hamster.

Authors:  G E Duffield; S McNulty; F J Ebling
Journal:  J Comp Neurol       Date:  1999-05-24       Impact factor: 3.215

2.  Potentiation of the resetting effects of light on circadian rhythms of hamsters using serotonin and neuropeptide Y receptor antagonists.

Authors:  G S Lall; M E Harrington
Journal:  Neuroscience       Date:  2006-06-05       Impact factor: 3.590

3.  Effect of chronic mild stress on circadian rhythms in the locomotor activity in rats.

Authors:  Z Gorka; E Moryl; M Papp
Journal:  Pharmacol Biochem Behav       Date:  1996-05       Impact factor: 3.533

4.  Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.

Authors:  E H Wong; M S Sonders; S G Amara; P M Tinholt; M F Piercey; W P Hoffmann; D K Hyslop; S Franklin; R D Porsolt; A Bonsignori; N Carfagna; R A McArthur
Journal:  Biol Psychiatry       Date:  2000-05-01       Impact factor: 13.382

5.  Reversed diurnal variation in depression: associations with a differential antidepressant response, tryptophan: large neutral amino acid ratio and serotonin transporter polymorphisms.

Authors:  Peter R Joyce; Richard J Porter; Roger T Mulder; Suzanne E Luty; Janice M McKenzie; Allison L Miller; Martin A Kennedy
Journal:  Psychol Med       Date:  2005-04       Impact factor: 7.723

6.  Diurnal variations of serotonin and dopamine levels in discrete brain regions of Syrian hamsters and their modification by chronic clorgyline treatment.

Authors:  N Ozaki; W C Duncan; K A Johnson; T A Wehr
Journal:  Brain Res       Date:  1993-11-05       Impact factor: 3.252

7.  Catecholaminergic innervation of the suprachiasmatic nucleus in the adult rat: ultrastructural relationships with neurons containing vasoactive intestinal peptide or vasopressin.

Authors:  H Jacomy; O Bosler
Journal:  Cell Tissue Res       Date:  1995-04       Impact factor: 5.249

8.  Neuroendocrine profiles in mood disorders.

Authors:  Paul Linkowski
Journal:  Int J Neuropsychopharmacol       Date:  2003-06       Impact factor: 5.176

9.  Local administration of serotonin agonists blocks light-induced phase advances of the circadian activity rhythm in the hamster.

Authors:  E T Weber; R L Gannon; M A Rea
Journal:  J Biol Rhythms       Date:  1998-06       Impact factor: 3.182

Review 10.  Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.

Authors:  Eberhard Fuchs; Maria Simon; Barthel Schmelting
Journal:  Int Clin Psychopharmacol       Date:  2006-02       Impact factor: 1.659

View more
  12 in total

1.  The effects of aging and chronic fluoxetine treatment on circadian rhythms and suprachiasmatic nucleus expression of neuropeptide genes and 5-HT1B receptors.

Authors:  Marilyn J Duncan; James M Hester; Jason A Hopper; Kathleen M Franklin
Journal:  Eur J Neurosci       Date:  2010-05       Impact factor: 3.386

2.  Brief constant light accelerates serotonergic re-entrainment to large shifts of the daily light/dark cycle.

Authors:  G Kaur; R Thind; J D Glass
Journal:  Neuroscience       Date:  2009-02-13       Impact factor: 3.590

3.  The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose.

Authors:  E M McGlashan; L S Nandam; P Vidafar; D R Mansfield; S M W Rajaratnam; S W Cain
Journal:  Psychopharmacology (Berl)       Date:  2018-09-15       Impact factor: 4.530

4.  Regulation of vasoactive intestinal polypeptide release in the suprachiasmatic nucleus circadian clock.

Authors:  Jessica M Francl; Gagandeep Kaur; John David Glass
Journal:  Neuroreport       Date:  2010-11-17       Impact factor: 1.837

5.  Selective serotonin reuptake inhibitors and raft inhibitors shorten the period of Period1-driven circadian bioluminescence rhythms in rat-1 fibroblasts.

Authors:  Kazumi Nomura; Oscar Castanon-Cervantes; Alec Davidson; Chiaki Fukuhara
Journal:  Life Sci       Date:  2008-04-16       Impact factor: 5.037

Review 6.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

7.  Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent.

Authors:  Gillian W Reierson; Claudio A Mastronardi; Julio Licinio; Ma-Li Wong
Journal:  Clin Pharmacol       Date:  2009-09-07

8.  Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity.

Authors:  Jonathan Shelton; Sujin Yun; Susan Losee Olson; Fred Turek; Pascal Bonaventure; Curt Dvorak; Timothy Lovenberg; Christine Dugovic
Journal:  Front Behav Neurosci       Date:  2015-01-15       Impact factor: 3.558

9.  Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway.

Authors:  Hongjie Zhu; Mikhail B Bogdanov; Stephen H Boyle; Wayne Matson; Swati Sharma; Samantha Matson; Erik Churchill; Oliver Fiehn; John A Rush; Ranga R Krishnan; Eve Pickering; Marielle Delnomdedieu; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

Review 10.  The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.

Authors:  Domenico De Berardis; Stefano Marini; Michele Fornaro; Venkataramanujam Srinivasan; Felice Iasevoli; Carmine Tomasetti; Alessandro Valchera; Giampaolo Perna; Maria-Antonia Quera-Salva; Giovanni Martinotti; Massimo di Giannantonio
Journal:  Int J Mol Sci       Date:  2013-06-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.